Chinese biotech startup Shenzhen Synthetica Pioneering raises Series A funding for oncolytic bacterial pipeline clinical trials.

Chinese biotech startup, Shenzhen Synthetica Pioneering, raised Series A funding led by Boehringer Ingelheim Venture Fund and Temasek. With additional participation from Lenovo Capital, Fosun Health Capital, and ATLATL Summer Fund, the company plans to accelerate its oncolytic bacterial pipelines into clinical trials for solid tumor treatments. Synthetica aims to create innovative, safe, and effective treatments that are versatile and minimally invasive for cancer patients.